|Mr. Thomas Bold||Pres, CEO, Interim CFO, Principal Accounting Officer & Director||100k||N/A||1961|
|Mr. Joseph Sierchio||Sec. & Director||N/A||N/A||1949|
|Ms. Patsy J. Trisler||VP of Regulatory & Clinical Affairs||60k||N/A||1948|
|Mr. Andrew Danielson||Director of Operations||N/A||N/A||N/A|
|Dr. Roger Esteban-Vives||Director of Cell Sciences||N/A||N/A||N/A|
RenovaCare, Inc., a development-stage company, focuses on the acquisition, research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. Its flagship technology product is CellMist System, which include a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. The company was formerly known as Janus Resources, Inc. and changed its name to RenovaCare, Inc. in January 2014. RenovaCare, Inc. is based in New York, New York.
RenovaCare, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.